SLRC Has the Solution: Our EAP System Makes Monoclonals Others Can't
01: Partnering
BioPharmaceutical companies use the EAP System™ to maximize the value of each antibody target.
02: Unmet opportunities
The distinct immune response generated by the EAP process consistently results in antibodies with higher affinities and necessary specificities. EAP may be the only way to develop antibodies to many important targets.
03: Predictability and speed
Minimize target-to-monoclonal time for entire target pool—as fast as 45 days from cDNA to MAb. Ideal for early functional validation of target sets. Low-, medium-, or high-throughput protocols are available.
04: The EAP difference:
You define the acceptance criteria for the antibody
We design and synthesize the immunogen—you avoid the cost and uncertainty
We screen for your acceptance criteria—not for binding to the immunogen
We deliver what you need—antibody, immunoassay, or test kit
